<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893759</url>
  </required_header>
  <id_info>
    <org_study_id>APG1252EC101</org_study_id>
    <nct_id>NCT04893759</nct_id>
  </id_info>
  <brief_title>A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors</brief_title>
  <official_title>A Phase IB Study of Safety, Efficacy and Pharmacokinetic of Intravenously Administered Pelcitoclax (APG-1252) in Patients With Advanced Neuroendocrine Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascentage Pharma Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascentage Pharma Group Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      APG-1252 is a highly potent Bcl-2 family protein inhibitor, a promising drug candidate which&#xD;
      shown high binding affinities to Bcl-2, Bcl-xL and Bcl-w. The preclinical studies have shown&#xD;
      that APG-1252 alone achieves complete and persistent tumor regression in multiple tumor&#xD;
      xenograft models with a twice weekly or weekly dose-schedule, including SCLC, colon, breast&#xD;
      and ALL cancer xenografts; achieves strong synergy with the chemotherapeutic agents,&#xD;
      indicating that APG-1252 may have a broad therapeutic potential for the treatment of human&#xD;
      cancer as a single agent and in combination with other classes of anticancer drugs. APG-1252&#xD;
      is intended for the treatment of patients with neuroendocrine tumors. The purpose of the&#xD;
      phase 1b study to establish the maximum tolerated dose (MTD), and/or recommended phase 2 dose&#xD;
      (RP2D). Preliminary efficacy and pharmacokinetic properties will be aslo evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) determination</measure>
    <time_frame>28 days</time_frame>
    <description>If ≥ 2/6 patients develop a DLT at any dose level, then the MTD will be assumed to have been exceeded. The dose level immediately below will then be expanded to 6 patients and, if no more than 1/6 patients develop DLT, then this dose will be declared the MTD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety data</measure>
    <time_frame>24 months</time_frame>
    <description>Incidence of adverse events (AEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy</measure>
    <time_frame>24 months</time_frame>
    <description>Objective response rate (ORR) assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy</measure>
    <time_frame>24 months</time_frame>
    <description>Progress free survival (PFS) assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy</measure>
    <time_frame>24 months</time_frame>
    <description>Disease control rate assessed (DCR) by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic</measure>
    <time_frame>28 days</time_frame>
    <description>Peak plasma concentration (Cmax)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>APG-1252</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pelcitoclax</intervention_name>
    <description>Multiple dose cohorts, 30 minute IV infusion, once a week, 28 days as a cycle</description>
    <arm_group_label>APG-1252</arm_group_label>
    <other_name>APG-1252</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed neuroendocrine tumors (G1, G2, G3).&#xD;
&#xD;
          2. Locally advanced or metastatic disease for which no standard therapy is judged&#xD;
             appropriate by the investigator.&#xD;
&#xD;
          3. Male or non-pregnant, non-lactating female patients age ≥18 years.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1.&#xD;
&#xD;
          5. Estimated life span ≥3 months.&#xD;
&#xD;
          6. At least one measurable lesion by RECIST 1.1.&#xD;
&#xD;
          7. Adequate hematologic and bone marrow functions.&#xD;
&#xD;
          8. Adequate renal and liver function.&#xD;
&#xD;
          9. Adequate cardiac function.&#xD;
&#xD;
         10. Brain metastases with clinically controlled neurologic symptoms.&#xD;
&#xD;
         11. Willingness to use contraception by a method that is deemed effective by the&#xD;
             investigator by both males and female patients of child bearing potential&#xD;
             (postmenopausal women must have been amenorrheal for at least 12 months to be&#xD;
             considered of non-childbearing potential) and their partners throughout the treatment&#xD;
             period and for at least three months following the last dose of study drug.&#xD;
&#xD;
         12. Ability to understand and willingness to sign a written informed consent form (the&#xD;
             consent form must be signed by the patient prior to any study-specific procedures).&#xD;
&#xD;
         13. Willingness and ability to comply with study procedures and follow-up examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neuroendocrine carcinoma (NEC).&#xD;
&#xD;
          2. Received chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy,&#xD;
             targeted therapy, biologic therapy, or any investigational therapy within 28 days&#xD;
             prior to the first dose of study drug; received TKIs within 5 x half-time.&#xD;
&#xD;
          3. Continuance of toxicities due to prior radiotherapy or chemotherapy agents that do not&#xD;
             recover to &lt; Grade 2.&#xD;
&#xD;
          4. Known bleeding diathesis/disorder.&#xD;
&#xD;
          5. Recent history of non-chemotherapy induced thrombocytopenia associated bleeding within&#xD;
             1 year prior to first dose of study drug.&#xD;
&#xD;
          6. Have active immune thrombocytopenic purpura (ITP), active autoimmune hemolytic anemia&#xD;
             (AIHA), or a history of being refractory to platelet transfusions (within 1 year prior&#xD;
             to the first dose of study drug).&#xD;
&#xD;
          7. Serious gastrointestinal bleeding within 3 months.&#xD;
&#xD;
          8. Use of therapeutic doses of anti-coagulants is excluded, along with anti-platelet&#xD;
             agents; low-dose anticoagulation medications that are used to maintain the patency of&#xD;
             a central intravenous catheter are permitted.&#xD;
&#xD;
          9. Failure to recover adequately, as judged by the investigator, from prior surgical&#xD;
             procedures. Patients who have had major surgery within 28 days from study entry, and&#xD;
             patients who have had minor surgery within 14 days of study entry.&#xD;
&#xD;
         10. Unstable angina, myocardial infarction, or a coronary revascularization procedure&#xD;
             within 180 days of study entry.&#xD;
&#xD;
         11. Uncontrolled concurrent illness including, but not limited to: serious uncontrolled&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             the study requirements.&#xD;
&#xD;
         12. Prior treatment with Bcl-2/Bcl-xL inhibitors.&#xD;
&#xD;
         13. Any other condition or circumstance of that would, in the opinion of the investigator,&#xD;
             make the patient unsuitable for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minhu Chen, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Chen, M.D., PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yifan Zhai, M.D., PhD.</last_name>
    <phone>+86-20-28068501</phone>
    <email>Yzhai@ascentage.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chen Yang, M.D.</last_name>
    <phone>+86-20-28068520</phone>
    <email>chen.yang@ascentage.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Zhang, Master</last_name>
      <email>86086692@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Gang Yuan, M.D.</last_name>
      <email>yuangang@mail.sysu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Minhu Chen, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ning Zhang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gang Yuan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Wang, M.D.</last_name>
      <email>wangwei@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Wei Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Chen, M.D., PhD.</last_name>
      <email>Chen0jie@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jian Zhang, M.D.</last_name>
      <email>syner2000@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xianjun Yu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jie Chen, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jian Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCL-2</keyword>
  <keyword>BCL-xl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

